Alaunos Acquires Velaris in Stock Merger, Secures $350 Million PIPE
Alaunos Therapeutics completed a stock-for-stock acquisition of Velaris and signed a $350 million PIPE to fund development of Velaris programs.
Alaunos Therapeutics completed the acquisition of Velaris in a stock-for-stock merger and lined up multiple supporting agreements to accelerate the combined company’s strategy. The company also signed a $350 million PIPE to fund development of Velaris programs, with board reconstitution and use-of…